Windlas Biotech Peer Comparison
NSE: WINDLAS | BSE: 543329
₹998.55
As on 28-Aug-2026IST
Market cap
₹2,064 Cr
Revenue (TTM)
₹942 Cr
P/E Ratio
31.1
P/B Ratio
3.9
Div. Yield
0.6 %
| Windlas Biotech | JB Chemicals | Pfizer | Caplin Point Lab | Eris Lifesciences | |
|---|---|---|---|---|---|
Market cap (₹ Cr) |
2,064 | 38,731 | 21,501 | 19,125 | 18,253 |
Revenue (₹ Cr) |
942 | 4,148 | 2,570 | 2,287 | 3,230 |
Net Profit (₹ Cr) |
66.42 | 709.47 | 735.15 | 678.07 | 666.92 |
Net Margin (%) |
6.92 | 16.85 | 26.88 | 28.10 | 20.60 |
RoE (%) |
11.91 | 19.11 | 19.16 | 19.73 | 18.75 |
Price to Earnings |
31.07 | 54.59 | 29.25 | 28.74 | 28.35 |
Price-To-Book |
3.88 | 9.31 | 4.88 | 5.08 | 4.51 |
Income Statement (₹ Cr)
| Windlas Biotech | JB Chemicals | Pfizer | Caplin Point Lab | Eris Lifesciences | |
|---|---|---|---|---|---|
|
Operating Revenue
|
904.09 | 4,147.79 | 2,519.65 | 1,937.47 | 2,893.64 |
|
Total Income
|
921.89 | 4,209.62 | 2,707.60 | 2,033.90 | 2,912.00 |
|
Total Expenditure
|
799.35 | 3,042.03 | 1,615.47 | 1,290.54 | 1,876.44 |
|
EBITDA
|
104.74 | 1,105.76 | 904.18 | 646.93 | 1,017.20 |
|
Depreciation
|
30.74 | 182.50 | 57.73 | 65.96 | 315.46 |
|
EBIT
|
74.00 | 923.26 | 846.45 | 580.97 | 701.74 |
|
Interest
|
4.83 | 5.57 | 9.57 | 0.61 | 231.29 |
|
Other Income
|
17.80 | 61.82 | 187.95 | 96.43 | 18.36 |
|
Exceptional Items
|
-- | -27.18 | -49.16 | -- | -- |
|
Profit before Tax
|
86.98 | 952.34 | 975.67 | 676.78 | 488.87 |
|
Provision for Tax
|
20.52 | 242.86 | 253.24 | 135.69 | 114.20 |
|
Profit after Tax
|
66.46 | 709.47 | 722.43 | 541.09 | 374.67 |
Liabilities (₹ Cr)
| Windlas Biotech | JB Chemicals | Pfizer | Caplin Point Lab | Eris Lifesciences | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
580.84 | 4,159.22 | 4,202.90 | 2,850.49 | 2,854.36 |
|
Minority Interest
|
-- | -- | -- | 35.90 | 417.40 |
|
Non-Current Liabilities
|
5.13 | 679.04 | 19.19 | 13.24 | 2,100.97 |
|
Current Liabilities
|
320.93 | 1,037.35 | 627.48 | 305.99 | 1,489.55 |
|
Total Liabilities
|
907.35 | 5,875.61 | 4,921.88 | 3,207.85 | 6,862.28 |
Assets (₹ Cr)
| Windlas Biotech | JB Chemicals | Pfizer | Caplin Point Lab | Eris Lifesciences | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
280.05 | 2,520.05 | 1,046.35 | 1,071.67 | 5,531.13 |
|
Current Assets
|
626.85 | 3,355.56 | 3,803.22 | 2,133.95 | 1,331.15 |
|
Total Assets
|
907.35 | 5,875.61 | 4,921.88 | 3,207.85 | 6,862.28 |
|
Total Debt*
|
29.88 | 0.00 | 2.50 | 0.55 | 2,421.66 |
|
Net Current Assets
|
305.92 | 2,318.21 | 3,175.74 | 1,827.96 | -158.40 |
|
Contingent Liabilities
|
-- | 106.98 | 370.49 | 0.64 | 64.29 |
Cashflow (₹ Cr)
| Windlas Biotech | JB Chemicals | Pfizer | Caplin Point Lab | Eris Lifesciences | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
104.93 | 703.92 | 967.57 | 432.37 | 1,065.01 |
|
Cash Flow from Investing Activities
|
-91.79 | -585.88 | -561.67 | -334.73 | -79.97 |
|
Cash from Financing Activities
|
-13.03 | -123.10 | -798.31 | -38.32 | -881.32 |
|
Net Cash Inflow / Outflow
|
0.11 | -5.05 | -392.41 | 59.32 | 103.72 |
Ratios
Profitability Ratios
| Windlas Biotech | JB Chemicals | Pfizer | Caplin Point Lab | Eris Lifesciences | |
|---|---|---|---|---|---|
|
ROCE (%)
|
16.06 | 25.19 | 23.39 | 26.22 | 13.59 |
|
ROE (%)
|
12.52 | 19.11 | 17.16 | 21.72 | 13.81 |
|
ROA (%)
|
7.97 | 13.01 | 14.91 | 18.37 | 5.48 |
|
EBIT Margin (%)
|
13.55 | 28.15 | 43.34 | 38.37 | 35.79 |
|
Net Margin (%)
|
7.21 | 16.85 | 26.68 | 26.60 | 12.87 |
|
Cash Profit Margin (%)
|
10.75 | 20.80 | 29.72 | 31.33 | 23.22 |
Growth Ratios
| Windlas Biotech | JB Chemicals | Pfizer | Caplin Point Lab | Eris Lifesciences | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
18.98 | 5.87 | 10.45 | 14.37 | 44.02 |
|
EBIT Growth (%)
|
9.29 | 9.10 | 19.68 | 20.21 | 48.22 |
|
Net Profit Growth (%)
|
8.96 | 7.56 | -5.88 | 17.27 | -5.65 |
|
EPS Growth (%)
|
8.20 | 4.29 | -5.88 | 17.25 | -10.39 |
|
Book Value Growth (%)
|
12.12 | 27.38 | -0.34 | 23.77 | 10.19 |
Valuation Ratios
| Windlas Biotech | JB Chemicals | Pfizer | Caplin Point Lab | Eris Lifesciences | |
|---|---|---|---|---|---|
|
Price / Earnings
|
23.43 | 46.69 | 29.89 | 28.38 | 54.83 |
|
Price / Book Value
|
2.77 | 7.96 | 5.14 | 5.52 | 6.78 |
|
Dividend Yield (%)
|
0.85 | 1.07 | 1.59 | 0.30 | 0.52 |
|
EV/EBITDA
|
12.93 | 28.25 | 16.93 | 19.78 | 20.75 |
|
Market Cap (₹ Cr)
|
1,556.84 | 33,126.34 | 21,592.90 | 15,219.80 | 19,292.77 |
Solvency Ratios
| Windlas Biotech | JB Chemicals | Pfizer | Caplin Point Lab | Eris Lifesciences | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.05 | 0.00 | 0.00 | 0.00 | 0.85 |
|
Short term debt to equity ratio
|
0.05 | 0.00 | 0.00 | 0.00 | 0.14 |
|
Current Ratio
|
1.95 | 3.23 | 6.06 | 6.97 | 0.89 |
|
Quick Ratio
|
1.76 | 2.58 | 5.31 | 5.88 | 0.67 |
|
Interest Coverage
|
19.02 | 172.03 | 102.95 | 1,110.48 | 3.11 |
Operating Efficiency Ratios
| Windlas Biotech | JB Chemicals | Pfizer | Caplin Point Lab | Eris Lifesciences | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
25.15 | 18.83 | 7.22 | 32.65 | 15.85 |
|
Asset Turnover
|
1.08 | 0.79 | 0.54 | 0.66 | 0.43 |
|
Receivable days
|
79.59 | 67.92 | 26.06 | 110.70 | 54.07 |
|
Inventory Days
|
28.91 | 51.58 | 65.95 | 65.86 | 32.16 |
|
Payable days
|
140.29 | 112.87 | 81.01 | 105.88 | 140.91 |
|
Cash Conversion Cycle
|
-31.79 | 6.63 | 11.00 | 70.68 | -54.68 |